Extracellular histones (None standardized; often referred to as 'extracellular histones' or by subunit name (e.g., H3, H4))

Extracellular histones are highly cationic nuclear proteins, usually involved in chromatin structure and gene regulation, which can be released into the extracellular space during severe cellular injury, infection, trauma, or cell death[1][3][4]. Once externalized, they act as damage-associated molecular pattern (DAMP) proteins, engaging innate immune receptors (primarily Toll-like receptors TLR2, TLR4, TLR9 and NLRP3 inflammasome) to trigger robust inflammatory responses, cytokine release, and cytotoxicity to endothelial, epithelial, neural, and vascular cells[1][3][4][5][6]. Extracellular histones also cause direct cell membrane damage through strong interactions with phospholipids, resulting in cell lysis, increased permeability, and induction of apoptosis and necrosis[7]. Their cytotoxic and procoagulant properties play a central role in the pathogenesis and severity of sepsis, trauma-induced systemic inflammatory response syndrome, ARDS, multi-organ dysfunction, and cardiovascular injury[2][4][5][6]. Both laboratory and clinical data confirm that increased levels of circulating extracellular histones—especially subunits H3 and H4—correlate with disease severity and organ failure in critically ill patients[2][4][6]. Therapeutic neutralization or blockade of extracellular histones with agents like activated protein C, heparin, polysialic acid, and anti-histone antibodies has demonstrated protective effects in animal models, but translation to clinical therapy is ongoing[3][4][7]. Safety concerns include the balance between reducing cytotoxicity and preserving necessary immune responses[4][7].

Other names

Circulating histonesHistone H3Histone H4Histone H1Extracellular nuclear histones

Neutralization of histone charge and cytotoxicity (e.g., heparin, CRP); Cleavage or blockade of histones (e.g., APC, anti-histone antibodies); Prevention of histone binding to cell membranes